Seung-min Park, professor at Nanyang Technological University and cofounder of Kanaria Health, is working to manufacture smart bidets that can capture biomarker data from urine and stool automatically and enable continuous monitoring.
Multisystem inflammatory syndrome in children (MIS-C), a serious disorder that develops after SARS-CoV-2 infection, could arise from latent infection of another pathogen, the Epstein-Barr virus (EBV). Researchers at Charité – Universitätsmedizin Berlin and the German Rheumatology Research Center (DRFZ) have linked the inflammatory effect of this co-infection with transforming growth factor β (TGF-β), ruling out the possibility that MIS-C is caused by an autoimmune reaction, or persistence of the coronavirus in the body.
Mucormycosis, a fungal infection caused by fungi from the order Mucorales, can cause severe disease, especially in immunocompromised subjects. These fungi are ubiquitous and can be found in environmental sources such as crop residues and soil. Among the multiple factors that increase the risk of mucormycosis infection are immunosuppression and diabetes mellitus.
Aim Vaccine Co. Ltd. may become the first company to gain regulatory clearance of a prophylactic iterative serum-free human rabies vaccine. Beijing-based Aim said it is preparing a regulatory submission of its independently developed rabies vaccine based on positive phase III results that showed good safety, immunogenicity and immune persistence.
Latest findings on Healios K.K.’s stem cell therapy to treat acute respiratory distress syndrome (ARDS), coined Multistem (invimestrocel; HLCM-051), found the regenerative medicine effective in reducing the number of patient days on ventilator treatment, as well as mortality benefits.
Japanese-founded Regcell Inc. has raised $45.8 million and is redomiciling to the U.S. to accelerate clinical development of its pioneering regulatory T-cell (Treg) platform for autoimmune diseases and transplantation.
China’s National Medical Products Administration (NMPA) approved the country’s first injectable teprotumumab biosimilar from Innovent Biologics Inc. under the brand name of Sycume (teprotumumab N-01) to treat thyroid eye disease on March 14. The NMPA on March 15 accepted Simcere Pharmaceutical Group Ltd.’s NDA of deunoxavir marboxil (ADC-189) tablets, a product originally developed by Jiaxing Andicon Biotech Co. Ltd. to treat influenza A and B.
Hypothermia is a marker of injury severity in patients with sepsis and shock, and for which debate still exists regarding its harmfulness and need for treatment. Hypothermia is also considered for many a defense mechanism. Animals given bacterial endotoxins usually exhibit cold-seeking behaviors.
Although several vaccines and drugs are available against SARS-CoV-2, the search for effective therapeutic agents for COVID-19 and future zoonotic coronaviruses continues. The RNA-dependent RNA polymerase (RdRp) is a relevant drug target in several RNA viral infections, such as SARS-CoV-2 (targeted by the approved drugs remdesivir and molnupiravir), hepatitis C, influenza and dengue viruses.
RSS
